<DOC>
	<DOCNO>NCT00998946</DOCNO>
	<brief_summary>The purpose study determine whether pralatrexate , give vitamin B12 folic acid , effective treatment relapse refractory B-cell Non-Hodgkin 's lymphoma ( NHL ) . The study also investigate safety pralatrexate vitamin B12 folic acid patient population . Additionally , study include collection blood sample investigate pharmacokinetics ( PK ) pralatrexate patient population ( PK activity drug body period time , include drug absorb , distribute body , localized tissue , excrete body ) .</brief_summary>
	<brief_title>Study Pralatrexate Treat Patients With Relapsed Refractory B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<criteria>Clinical diagnosis Bcell NonHodgkin 's Lymphoma , use Revised European American Lymphoma ( REAL ) World Health Organization ( WHO ) disease classification Measurable disease Progressive persistent disease ≥ 1 prior treatment ( ) Recovered toxic effect prior treatment At least 4 week since recent cytotoxic therapy Easter Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Adequate blood , liver , kidney function define laboratory level 1.0 mg/day orally folic acid least 7 day prior &amp; 1 mg intramuscular vitamin B12 within 10 week plan start pralatrexate Females childbearing potential must agree use medically acceptable birth control start pralatrexate least 30 day last administration pralatrexate must negative serum pregnancy test within 14 day prior first day study treatment Males surgically sterile must agree use medically acceptable birth control start pralatrexate least 90 day last administration pralatrexate Available repeat dose followup Able give write informed consent Relapsed patient diffuse large Bcell lymphoma ( DLBCL ) candidate highdose therapy autologous stem cell transplantation ( SCT ) highdose therapy autologous SCT standard curative option Active concurrent malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) . If history prior malignancy exception list , patient must diseasefree ≥ 5 year . Patients prior malignancy &lt; 5 year study entry may still enrol receive treatment result complete resolution cancer currently clinical , radiologic , laboratory evidence active recurrent disease Congestive heart failure Class III/IV accord New York Heart Association Functional Classification Uncontrolled hypertension Known human immunodeficiency virus ( HIV ) positive diagnosis Symptomatic central nervous system ( CNS ) metastases lesion treatment require . Patients receive prophylactic CNS treatment eligible . Patients undergone allogeneic SCT Patients relapse &lt; 100 day time autologous SCT Patients disease refractory peripheral blood SCT relapse &lt; 100 day time transplant Active uncontrolled infection , underlie medical condition , serious illness would impair ability patient receive protocol treatment . Major surgery within 14 day enrollment Receipt conventional chemotherapy radiation therapy ( encompass substantial [ &gt; 10 % ] amount bone marrow ) within 4 week ( 6 week nitrosoureas mitomycin C ) prior study treatment plan use course study Receipt systemic corticosteroid within 1 week study treatment , unless patient take continuous dose 10 mg/day prednisone equivalent least 1 month Use investigational drug , biologics , device within 4 week prior study treatment plan use course study Previous exposure pralatrexate Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Non-Hodgkin 's</keyword>
</DOC>